New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
08:08 EDTCLSNCelsion announces positive results from Phase III HEAT Study of ThermoDox
Celsion announced that the latest overall survival data from its post-hoc analysis of results from the Company's Phase III HEAT Study of ThermoDox, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radio frequency ablation, supports the continued clinical development of ThermoDox in a prospective pivotal Phase III Study, subject to regulatory review and agreement. As provided for in the HEAT Study's Special Protocol Assessment, or SPA, agreement with the FDA the Company continues to follow patients for overall survival, the secondary endpoint of the Study. Data from four quarterly reviews of overall survival have been evaluated since the announcement of top line PFS data.
News For CLSN From The Last 14 Days
Check below for free stories on CLSN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 28, 2014
08:08 EDTCLSNCelsion's ThermoDox for liver cancer shows positive overall survival data
Subscribe for More Information
July 24, 2014
08:18 EDTCLSNCelsion's Thermodox for breast cancer shows positive Phase 2 results
Celsion announced positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox in Recurrent Chest Wall Breast Cancer. 60% of patients experienced a stabilization of their highly refractory disease with a local response rate of 50% observed in the 10 evaluable patients, notably 3 complete responses, 2 partial responses and 1 patient with stable disease. These data are consistent with the previously reported positive Phase 1 data in RCWBC.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use